keyword
MENU ▼
Read by QxMD icon Read
search

abatacept rheumatoid arthritis

keyword
https://www.readbyqxmd.com/read/29046115/bone-and-the-immune-system
#1
M Neale Weitzmann
Osteoporosis increases fracture risk, a cause of crippling morbidity and mortality. The immunoskeletal interface (ISI) is a centralization of cell and cytokine effectors shared between skeletal and immune systems. Consequently, the immune system mediates powerful effects on bone turnover. Physiologically, B cells secrete osteoprotegerin (OPG), a potent anti-osteoclastogenic factor that preserves bone mass. However, activated T cells and B cells secrete pro-osteoclastogenic factors including receptor activator of Nuclear factor-kappaB (NF-kB) ligand (RANKL), Interleukin (IL)-17A, and tumor necrosis factor (TNF)-α promoting bone loss in inflammatory states such as rheumatoid arthritis...
January 1, 2017: Toxicologic Pathology
https://www.readbyqxmd.com/read/29043142/costimulation-pathway-blockade-in-kidney-transplant-recipients-with-de-novo-rheumatoid-arthritis
#2
Mohamed Sheta, Samy Riad, Udayakumar Deepak, Naim Issa, Mark Birkenbach, Hassan N Ibrahim, Aleksandra Kukla
The best approach to treatment of de-novo rheumatoid arthritis in solid organ transplant recipients on typical immunosuppression is not well established. The use of biologics targeting specific cell types, cytokines, and immunological pathways has been gaining interest in the treatment of both, auto- and alloimmunity. We present a case of de-novo rheumatoid arthritis in a kidney transplant recipient 10 years post-transplant while receiving cyclosporine, mycophenolate mofetil, and also prednisone. Initial presentation included features of polymyalgia rheumatica and nephrotic range proteinuria...
2017: Clin Nephrol Case Stud
https://www.readbyqxmd.com/read/29039054/treatment-persistence-and-healthcare-costs-among-patients-with-rheumatoid-arthritis-changing-biologics-in-the-usa
#3
Benjamin Chastek, Chieh-I Chen, Clare Proudfoot, Shraddha Shinde, Andreas Kuznik, Wenhui Wei
INTRODUCTION: After a patient with rheumatoid arthritis (RA) fails tumor necrosis factor inhibitor (TNFi) treatment, clinical guidelines support either cycling to another TNFi or switching to a different mechanism of action (MOA), but payers often require TNFi cycling before they reimburse switching MOA. This study examined treatment persistence, cost, and cost per persistent patient among MOA switchers versus TNFi cyclers. METHODS: This study of Commercial and Medicare Advantage claims data from the Optum Research Database included patients with RA and at least one claim for a TNFi (adalimumab, certolizumab pegol, etanercept, golimumab, or infliximab) between January 2012 and September 2015 who changed to another TNFi or a different MOA therapy (abatacept, tocilizumab, or tofacitinib) within 1 year...
October 16, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29037899/the-management-of-first-line-biologic-therapy-failures-in-rheumatoid-arthritis-current-practice-and-future-perspectives
#4
REVIEW
Ennio Giulio Favalli, Maria Gabriella Raimondo, Andrea Becciolini, Chiara Crotti, Martina Biggioggero, Roberto Caporali
The introduction of biologic disease-modifying anti-rheumatic drugs (bDMARDs) has dramatically changed the management of rheumatoid arthritis (RA). However, in a real-life setting about 30-40%. of bDMARD treated patients experience drug discontinuation because of either inefficacy or adverse events. According to international recommendations, to date the best strategy for managing first-line bDMARD failures has not been defined yet and available data (especially on TNF inhibitors [TNFis]) seem to drive toward a personalized approach for the individual patient...
October 13, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29024421/generalized-estimating-equation-model-to-compare-drug-effects-on-synovitis-of-the-dominant-wrist-in-severe-rheumatoid-arthritis-between-tocilizumab-versus-adalimumab-versus-abatacept-using-high-resolution-ultrasound
#5
Ying-Chou Chen, Wen-Chan Chiu, Fu-Mei Su, Jia-Feng Chen
PURPOSE: The use of biological agents has revolutionized the treatment of rheumatoid arthritis (RA). However, details of serial synovial changes in imaging evaluation are unclear. Using power Doppler (PD) ultrasound, this study aimed to evaluate the comparative efficacy of biologicals for patients with refractory RA, with the hope that these findings could aid in clinical decision making. METHODS: Patients with RA who received abatacept, adalimumab or tocilizumab therapy were enrolled...
October 12, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29023282/abatacept-monotherapy-versus-abatacept-plus-methotrexate-for-treatment-refractory-rheumatoid-arthritis
#6
Tristan Pascart, Peggy Philippe, Elodie Drumez, Xavier Deprez, Bernard Cortet, Alain Duhamel, Eric Houvenagel, René-Marc Flipo
BACKGROUND: Methotrexate combination therapy improves abatacept efficacy as a first-line biologic agent for the treatment of rheumatoid arthritis, but it is unclear when abatacept is used later on, particularly after non-TNF inhibitor (TNFi) failure. STUDY QUESTION: The objective of this study was to determine whether treatment response after non-TNFi inadequate response is different in patients with rheumatoid arthritis (RA) treated with abatacept in combination with or not with methotrexate...
September 12, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28980085/real-world-experience-of-tocilizumab-in-rheumatoid-arthritis-sub-analysis-of-data-from-the-italian-biologics-register-gisea
#7
F Iannone, G Ferraccioli, L Sinigaglia, E G Favalli, P Sarzi-Puttini, F Atzeni, R Gorla, C Bazzani, M Govoni, I Farina, E Gremese, A Carletto, A Giollo, M Galeazzi, R Foti, L Bianchino, L La Grasta, G Lapadula
To assess the long-term effectiveness and safety of tocilizumab, abatacept, and tumor necrosis factor-α inhibitors (TNFi), in the Italian real-world setting of rheumatoid arthritis (RA). The records of adult RA patients from the Italian biologics' registry Gruppo Italiano Studio Early Arthritis (GISEA) were analyzed. Demographic and clinical data were obtained at entry. The disease remission rate (28-joint disease activity score calculated using the erythrocyte sedimentation rate [DAS28-ESR] ≤ 2.6) and frequency of adverse events (AEs) were evaluated at 2 years...
October 5, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28975211/malignant-neoplasms-in-patients-with-rheumatoid-arthritis-treated-with-tumor-necrosis-factor-inhibitors-tocilizumab-abatacept-or-rituximab-in-clinical-practice-a-nationwide-cohort-study-from-sweden
#8
Hjalmar Wadström, Thomas Frisell, Johan Askling
Importance: Considering the widespread and increasing use of biological immunomodulators (biological disease-modifying antirheumatic drugs [bDMARDs]) to treat chronic inflammatory conditions, and the concern that immunomodulation may alter cancer risk and progression, the limited available data on use of these therapies as used in clinical practice and cancer risks are a concern. Objective: To assess the risk of incident malignant neoplasms in patients with rheumatoid arthritis (RA) treated with bDMARDs...
September 18, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28967792/abatacept-and-granulocyte-colony-stimulating-factor-in-a-patient-with-rheumatoid-arthritis-and-neutropenia
#9
Marta Priora, Simone Parisi, Marco Scarati, Richard Borrelli, Clara Lisa Peroni, Enrico Fusaro
Neutropenia in patients with inflammatory diseases increases the risk of infection due to the disease itself and the related immunosuppressive treatments. We report the case of a 54-year-old female with rheumatoid arthritis and following development of chronic neutropenia. All investigations excluded pathogenic relations with drugs and/or other clinical situations; the gravity of neutropenia required a treatment with G-CSF and the increased articular inflammatory activity justified a biologic-therapy, abatacept (CTLA4 inhibitors)...
October 2017: Immunotherapy
https://www.readbyqxmd.com/read/28939234/persistence-of-biologic-disease-modifying-antirheumatic-drugs-in-patients-with-rheumatoid-arthritis-an-analysis-of-the-south-korean-national-health-insurance-database
#10
Min-Young Lee, Ju-Young Shin, Sun-Young Park, Donguk Kim, Hoon-Suk Cha, Eui-Kyung Lee
OBJECTIVES: This study examined and compared the persistence of adalimumab, etanercept, infliximab, or abatacept as first- and subsequent-line treatment for rheumatoid arthritis in the South Korean clinical practice. METHODS: We conducted a retrospective cohort study with patients receiving adalimumab, etanercept, infliximab, or abatacept between July 1, 2009 and December 31, 2012, using the nationwide Korean National Health Insurance database. Patients who were receiving a newly initiated biologic treatment and those who switched from other biologic treatment were identified and classified into first- and subsequent-use cohorts, respectively...
August 31, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28877634/certolizumab-an-anti-tnf-safe-during-pregancy-the-crib-study-results-an-interview-with-professor-xavier-mariette
#11
Xavier Mariette
Professor Xavier Mariette, MD, PhD, has served as the Head of the Rheumatology Department of Bicêtre Hospital, Paris-Sud University since 1999, a role he took following 10 years of practice of clinical immunology. Professor Mariette has initiated a number of clinical research studies on biotherapies in autoimmune diseases. He is the head of the French RATIO (Research Axed on Tolerance of Biotherapy) observatory, collecting specific rare serious adverse events in patients treated with anti-TNF. He initiated the French AIR (Autoimmunity and Rituximab) and ORA (Orencia and Rheumatoid arthritis) registries of patients with autoimmune diseases treated with rituximab and abatacept...
September 2017: Immunotherapy
https://www.readbyqxmd.com/read/28852832/down-titration-of-biologics-for-the-treatment-of-rheumatoid-arthritis-a-systematic-literature-review
#12
Chak Sing Lau, Allan Gibofsky, Nemanja Damjanov, Sadiq Lula, Lisa Marshall, Heather Jones, Paul Emery
Biologic therapies have improved the management of rheumatoid arthritis (RA) and the treat-to-target approach has resulted in many patients achieving remission. In the current treatment landscape, clinicians have begun considering dose reduction/tapering for their patients. Rheumatology guidelines in Asia, Europe, and the United States include down-titration of biologics but admit that the level of evidence is moderate. We conducted a systematic literature review to assess the published studies that evaluate down-titration of biologics in RA...
August 29, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28837415/the-efficacy-of-abatacept-focusing-on-anti-ccp-antibody-in-japanese-patients-with-rheumatoid-arthritis-for-104-weeks
#13
Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ryo Hiroshima, Kosei Kawakami, Naoko Koenuma, Mina Ishibashi, Shigeki Momohara
No abstract text is available yet for this article.
August 24, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28822046/body-mass-index-and-clinical-response-to-intravenous-or-subcutaneous-abatacept-in-patients-with-rheumatoid-arthritis
#14
Maria-Antonietta D'Agostino, Rieke Alten, Eduardo Mysler, Manuela Le Bars, June Ye, Bindu Murthy, Julia Heitzmann, Radu Vadanici, Gianfranco Ferraccioli
This post hoc analysis of ACQUIRE (NCT00559585) explored the effect of baseline body mass index (BMI) on the pharmacokinetics of and clinical response to subcutaneous (SC) or intravenous (IV) abatacept in patients with rheumatoid arthritis (RA). ACQUIRE was a phase 3b, 6-month, double-blind, double-dummy study in which patients with RA were randomized (1:1) to SC (fixed - dose; 125 mg/week) or IV (weight-tiered; ~ 10 mg/kg/month) abatacept plus methotrexate. In this analysis, minimum abatacept plasma concentration (Cmin) was measured at 3 and 6 months, and clinical remission over 6 months was assessed by Disease Activity Score 28 (C-reactive protein; DAS28 [CRP], < 2...
August 18, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28794381/clinical-characteristics-of-rheumatoid-arthritis-patients-achieving-functional-remission-after-six-months-of-non-tumor-necrosis-factor-biological-disease-modifying-antirheumatic-drugs-dmards-treatment
#15
Yusuke Miwa, Mayu Saito, Hidekazu Furuya, Ryo Yanai, Yuzo Ikari, Tomoki Hayashi, Tsuyoshi Kasama, Yoichi Toyoshima, Katsunori Inagaki
Objectives We aimed to identify the factors that predict the likelihood of remission based on a health assessment questionnaire (HAQ) in rheumatoid arthritis (RA) patients who received non-tumor necrosis factor (TNF) biologics for six months before they commenced definitive treatment. Methods The subjects consisted of 97 RA patients treated with tocilizumab or abatacept for 6 months. The following characteristics were investigated: age, gender, body mass index, steroid and methotrexate dosage, serum matrix metalloproteinase-3 levels, simplified disease activity index (SDAI) score, HAQ score (for assessing the activities of daily living [ADL]) and the short form (SF)-36 score (for assessing the quality of life [QOL])...
September 1, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28791875/incidence-of-dose-escalation-and-impact-on-biologic-costs-among-patients-with-rheumatoid-arthritis-treated-with-three-intravenous-agents
#16
Anagha Nadkarni, Donna McMorrow, Chad Patel, Robert Fowler, David Smith
AIM: Evaluation of dose escalation and costs among rheumatoid arthritis patients treated with intravenous abatacept, intravenous infliximab or intravenous tocilizumab. MATERIALS & METHODS: Adults with rheumatoid arthritis and biologic treatment were identified from the MarketScan(®) Research databases. Study outcomes included dose escalation, per-patient per-month (PPPM) biologic costs and PPPM all-cause total healthcare costs. Impact of dose escalation on biologic costs was estimated using multivariate analyses...
August 9, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28791873/comparing-biologic-persistence-and-healthcare-costs-in-rheumatoid-arthritis-patients-initiating-subcutaneous-biologics
#17
Anagha Nadkarni, Donna McMorrow, Robert Fowler, David Smith
AIM: Comparing biologic persistence and healthcare costs between rheumatoid arthritis (RA) patients initiating first- or second-line subcutaneous abatacept, adalimumab, or etanercept. MATERIALS & METHODS: Retrospective, observational cohort study, which included adults with RA who initiated either of the three treatments between 29 July 2011 and 1 July 2015. Total healthcare costs were measured during baseline and follow-up. Biologic persistence was compared using multivariable Cox proportional hazards regression...
August 9, 2017: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/28765712/mean-cost-per-number-needed-to-treat-with-tocilizumab-plus-methotrexate-versus-abatacept-plus-methotrexate-in-the-treatment-of-rheumatoid-arthritis-in-patients-previously-treated-with-methotrexate
#18
Maurizio Benucci, Roberto Ravasio, Arianna Damiani
INTRODUCTION: Biological disease-modifying antirheumatic drugs are particularly recommended for use in patients who are poor responders, are intolerant to conventional disease-modifying antirheumatic drugs (cDMARDs), or in whom continued treatment with cDMARDs is deemed inappropriate. We estimated the efficacy and treatment costs associated with the use of tocilizumab (TCZ) plus methotrexate (Mtx) versus abatacept (ABT) plus Mtx in the treatment of rheumatoid arthritis (RA) in patients previously treated with Mtx...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28739353/incidence-of-tuberculosis-among-patients-with-rheumatoid-arthritis-using-tnf-blockers-in-brazil-data-from-the-brazilian-registry-of-biological-therapies-in-rheumatic-diseases-registro-brasileiro-de-monitora%C3%A3-%C3%A3-o-de-terapias-biol%C3%A3-gicas-biobadabrasil
#19
Claudia Leiko Yonekura, Rene Donizeti Ribeiro Oliveira, David C Titton, Roberto Ranza, Aline Ranzolin, André L Hayata, Ângela Duarte, Inês G Silveira, Hellen M da S de Carvalho, Júlio C Bertacini de Moraes, Mirhelen Mendes de Abreu, Valéria Valim, Washington Bianchi, Claiton Viegas Brenol, Ivanio A Pereira, Izaias Costa, José C Macieira, José R S Miranda, Luiz S Guedes-Barbosa, Manoel B Bertolo, Maria Fátima Lobato da C Sauma, Marília B G Silva, Marlene Freire, Morton A Scheinberg, Roberto A Toledo, Sheila K F Oliveira, Vander Fernandes, Marcelo M Pinheiro, Glaucio Castro, Walber Pinto Vieira, Cesar Emile Baaklini, Antonio Ruffino-Netto, Geraldo da Rocha Castelar Pinheiro, Ieda Maria Magalhães Laurindo, Paulo Louzada-Junior
OBJECTIVES: To assess the incidence of tuberculosis and to screen for latent tuberculosis infection among Brazilians with rheumatoid arthritis using biologics in clinical practice. PATIENTS AND METHODS: This cohort study used data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitoração de Terapias Biológicas - BiobadaBrasil), from 01/2009 to 05/2013, encompassing 1552 treatments, including 415 with only synthetic disease-modifying anti-rheumatic drugs, 942 synthetic DMARDs combined with anti-tumor necrosis factor (etanercept, infliximab, adalimumab) and 195 synthetic DMARDs combined with other biologics (abatacept, rituximab and tocilizumab)...
2017: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/28730687/efficacy-of-abatacept-in-patients-with-rheumatoid-arthritis-as-assessed-by-magnetic-resonance-imaging-of-bilateral-hands
#20
Yuji Kukida, Akiko Kasahara, Takahiro Seno, Takuya Inoue, Risa Sagawa, Takashi Kida, Amane Nakabayashi, Hidetake Nagahara, Ken Murakami, Toshifumi Sugitani, Satoshi Morita, Hirotoshi Ito, Ryo Oda, Hiroyoshi Fujiwara, Masataka Kohno, Yutaka Kawahito
AIM: To examine the efficacy of abatacept in patients with rheumatoid arthritis (RA) using magnetic resonance imaging (MRI) of bilateral hands. METHOD: This prospective study included 35 RA patients. MRI of bilateral hands was performed at baseline and after 12 months of treatment with intravenous abatacept. MRI images were scored for synovitis, osteitis, erosion and joint space narrowing (JSN) according to the RA MRI Scoring System (RAMRIS). The primary endpoint was the change in RAMRIS score from baseline...
July 21, 2017: International Journal of Rheumatic Diseases
keyword
keyword
94163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"